MPO density in primary cancer biopsies of ovarian carcinoma enhances the indicative value of IL-17 for chemosensitivity

Table 2 Patients’ characteristics according to dichotomized distribution of MPO in the overall cohort (n = 47)^a

	MPO high	MPO low	p-value
	n = 12 (100 %)	n = 35 (100 %)	p-value
Age (median, range)	55 (45–73)	60 (34–77)	0.196
FIGO stage
II	0	1 (2.9)	0.401
IIIA	0	1 (2.9)
IIIB	3 (25.0)	2 (5.7)
IIIC	7 (58.3)	25 (71.4)
IV	2 (16.7)	6 (17.1)
Residual disease
None	4 (33.3)	12 (34.3)	0.919
<2 cm	5 (41.7)	12 (34.3)
>2 cm	3 (25.0)	10 (28.6)
Numbers of chemotherapy cycles
<6	1 (8.3)	6 (17.1)	0.440
6 or more	11 (91.7)	28 (80.0)	0.440
Primary cancer biopsies
CS^b	10 (83.3)	23 (65.7)	0.249
CR^b	2 (16.7)	12 (34.3)	0.249
Recurrent cancer biopsies (n = 10/35)
CS^b	9 (90.0)	23 (65.7)	0.135
CR^b	1 (10.0)	12 (34.3)	0.135
RFS^c (mean/SE)	11.9 (2.7)	9.5 (1.6)	0.380
OS^c (mean/SE)	56.8 (14.4)	39.3 (4.4)	0.139

^apercentages may not add to 100 % due to missing values of defined variables, missing clinicopathological information was assumed to be missing at random. Variables are indicated as absolute numbers, %, median or range. Age, RFS and OS were evaluated using the Kruskal-Wallis test. FIGO stage, residual disease, numbers of chemotherapy cycles and chemoresistance were analyzed using the Chi-Square or the Fisher’s Exact test
^bCS chemosensitive, CR chemoresistant
^cRFS recurrence-free survival, OS overall survival

ISSN: 1471-2407